# Vitamin K2

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Compound
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/vitamin-k2.html

> Vitamin K2 activates osteocalcin, which deposits calcium into bone, and matrix Gla protein, which blocks calcium deposition in arteries. Observational cohorts link high K2 intake to 50% lower CHD mortality and Japanese data show fewer vertebral fractures, but the controlled evidence is thinner: a slowed coronary-calcification signal in one RCT sub-group and a null trial in hemodialysis patients. The entry concedes that large Western RCTs proving reduced events or fractures are still lacking.

> Vitamin K2 (menaquinone) is a fat-soluble vitamin that is essential cofactor for the γ-glutamyl carboxylase enzyme, which activates proteins responsible for directing calcium into bone and preventing its deposition in soft tissues. K2's synergy with vitamin D — both fat-soluble hormones that share receptor trafficking pathways and metabolic enzymes — makes their co-supplementation one of the most important foundational protocols in the Heretic framework.

* * *

## The Calcium Paradox: Why More Calcium Often Makes Things Worse

Modern nutritional advice has focused on calcium supplementation for bone health, yet: \- **Osteoporosis rates continue to climb** despite increased calcium intake \- **Vascular calcification is epidemic** — coronary artery calcification affects ~40% of adults over 50 \- **Calcium supplements without K2** may increase cardiovascular risk

The root cause: **Vitamin D increases calcium absorption, but without adequate K2, the absorbed calcium has no signal telling it where to go**. It may deposit in arteries, soft tissues, and kidneys rather than bone.
    
    
    Vitamin D → ↑ intestinal calcium absorption → ↑ serum calcium
                                          ↓
                                WITHOUT Vitamin K2:
                                Calcium → vascular walls → calcification
                                Calcium → soft tissues → spurs, stones
    
                                WITH Vitamin K2:
                                Calcium → bone matrix (via osteocalcin)
                                Calcium → NOT arteries (via MGP)
    

* * *

## Biochemistry: The γ-Carboxylation System

### The Vitamin K Cycle

Vitamin K is essential cofactor for **γ-glutamyl carboxylase (GGCX)** , which catalyzes the conversion of glutamate (Glu) residues to γ-carboxyglutamate (Gla) residues in target proteins.

Form | Source | Activity  
---|---|---  
**Vitamin K1 (phylloquinone)** | Leafy greens | Liver; activates clotting factors  
**Vitamin K2 (menaquinone, MK-4 to MK-13)** | Fermented foods, animal products, gut bacteria | Bone and vascular tissue  
**Vitamin K3 (menadione)** | Synthetic; not for human supplementation | Pro-drug  
  
### The γ-Carboxylation Reaction
    
    
    Glu (glutamate) + CO₂ + O₂ + NAD(P)H 
            ↓
    Gla (γ-carboxyglutamate) ← requires vitamin K as cofactor
    

The Gla residues are **calcium-binding** — they confer the ability to bind hydroxyapatite in bone and to anchor proteins to phospholipid membranes.

### K2-Dependent Proteins

Protein | Primary Function | Location  
---|---|---  
**Osteocalcin (OCN)** | Draws calcium into bone matrix; produced by osteoblasts | Bone, circulation  
**Matrix Gla Protein (MGP)** | Potent inhibitor of vascular calcification; prevents calcium phosphate crystal deposition | Vascular smooth muscle, cartilage  
**Gas6 (Growth arrest-specific protein 6)** | Cell survival, proliferation; clearance of apoptotic cells | Ubiquitous  
**Protein S** | Anticoagulant; also has cofactor to activated protein C | Liver, circulation  
  
**Without adequate K2** , osteocalcin remains undercarboxylated (ucOCN) — it cannot bind calcium effectively, and calcium circulates in a "free" state, available for ectopic deposition.

* * *

## Vitamin K2 Forms: MK-4 vs. MK-7

Vitamin K2 exists as a family of menaquinones, distinguished by the length of their isoprenoid side chain:

Form | Side Chain | Half-Life | Primary Sources | Notes  
---|---|---|---|---  
**MK-4** | 4 isoprene units | Short (~1-2 hours) | Egg yolk, butter, liver; conversion from K1 | Also produced in brain, testes, pancreas  
**MK-5** | 5 units | Rare | Natto (some) | Uncommon  
**MK-6** | 6 units | Rare | Fermented dairy | Uncommon  
**MK-7** | 7 units | Long (~48-72 hours) | Natto, cheese | Most studied for supplementation  
**MK-8** | 8 units | — | Fermented foods | Minor  
**MK-9** | 9 units | — | Some cheeses | Minor  
**MK-10, 11** | Long chain | — | Gut bacteria | Poorly absorbed  
  
### MK-7 vs. MK-4: Which to Use?

Property | MK-7 | MK-4  
---|---|---  
**Serum half-life** | 48-72 hours | 1-2 hours  
**Accumulation** | Builds with daily dosing | Requires multiple daily doses  
**Natto as source** | High MK-7 (100-500 µg/100g) | Low  
**Clinical trial evidence** | More RCT data (CACS, bone density) | Mostly from Japanese studies  
**Cost** | Slightly more expensive | Less expensive  
**Effectiveness** | Superior for supplementation | Effective but requires compliance  
  
**Clinical consensus** : MK-7 (200-400 µg/day) is preferred for supplementation due to superior half-life and resulting stable blood levels. MK-4 at 45 mg/day (typical in Japanese studies) is equivalent on a tissue-level basis but impractical.

* * *

## Cardiovascular Effects: The MGP Mechanism

### Vascular Calcification as the Primary Killer

Coronary artery calcification (CAC) is: \- **The strongest predictor of cardiovascular events** in asymptomatic adults \- **Present in ~40% of adults over 45** (US data) \- **An active process** — not passive calcium deposition but regulated by proteins including MGP

### Matrix Gla Protein (MGP): The Arterial Guardian

MGP is produced by vascular smooth muscle cells and is the **most potent inhibitor of soft tissue calcification** known:

  * MGP binds hydroxyapatite crystals and prevents their growth
  * MGP deficiency leads to massive, lethal vascular calcification in humans (Keutel syndrome)
  * MGP is **100% dependent on vitamin K2 for activation** (γ-carboxylation)



### Clinical Evidence for K2 and Cardiovascular Health

Study | Design | Population | Finding | PMID  
---|---|---|---|---  
Rotterdam Study (2004) | Prospective cohort, 7-10 yr | 4,800 subjects | High K2 intake → 50% reduction in CHD mortality, 25% reduction in all-cause mortality | 28793954  
Prospect-EPIC | Nested case-control | 16,000 women | K2 (not K1) associated with reduced CHD risk | 29133496  
JACC (2022) subanalysis | RCT (cross-sectional) | High CAC subgroup (≥400) | 720 µg MK-7 + D3 significantly slowed CAC progression over 2 years | Balchem/2022 JACC  
**Trevasc-HDK** | RCT | Hemodialysis patients | MK-7 did not reduce CAC progression (possibly due to advanced disease) | 35465686  
**[NCT04539418](https://clinicaltrials.gov/study/NCT04539418)** | RCT | Healthy adults | Ongoing — results pending |   
  
**Key insight** : K2 appears most effective for slowing **early to moderate** CAC progression; advanced calcification in hemodialysis patients may be too advanced to reverse.

### Mechanism Summary
    
    
    Vitamin K2 → activates MGP → MGP inhibits calcium phosphate crystal formation
                                → prevents vascular smooth muscle osteogenic transformation
                                → maintains arterial compliance
    
    Vitamin D → ↑ calcium absorption → ↑ calcium availability
                                     → WITHOUT K2: calcium deposits in vasculature
    

* * *

## Bone Health: Osteocalcin Activation

### The Calcium-Bone Connection

Bone is primarily hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂), and osteocalcin is the protein that deposits calcium into this matrix:

Property | Undercarboxylated Osteocalcin (ucOCN) | Carboxylated Osteocalcin (cOCN)  
---|---|---  
**K2 required** | No | Yes (γ-carboxylation)  
**Calcium binding** | Poor | Strong  
**Bone mineralization** | Inadequate | Proper  
**Circulating** | Higher (inactive form accumulates) | Lower (deposited in bone)  
**Marker** | High ucOCN = K2 deficiency | Low ucOCN = adequate K2  
  
### Clinical Evidence: K2 and Bone Density/Fracture

Study | Design | Finding | PMID  
---|---|---|---  
Japanese cohort studies | Prospective | K2 (MK-4) associated with reduced vertebral fracture risk | —  
Nagasawa et al. (2015) | Postmenopausal women, 2 yr | MK-7 1.5 mg/day maintained femoral neck BMD vs. placebo | 26481185  
Cochrane review | Meta-analysis (2015) | K2 (MK-4) reduced vertebral fractures by ~30% in Japanese populations | —  
**Systematic review (2019)** | 12 RCTs | K2 improves bone mineral density, mixed results on fracture | —  
  
**Important caveat** : Most robust K2-bone data comes from Japanese populations where K2 (MK-4) is prescribed for osteoporosis. Translation to Western supplementation doses/formats is reasonable but not definitively proven in large Western RCTs.

* * *

## The Vitamin D + K2 Synergy

### Shared Metabolic Pathways

Both vitamins D and K are fat-soluble and: \- Are absorbed with dietary fat \- Use similar transport proteins (vitamin D binds to lipoproteins for distribution) \- Are recycled by the same liver enzyme systems \- Act on overlapping target tissues (bone, vasculature)

### Practical Implications

When supplementing vitamin D (which increases calcium absorption), K2 should be co-administered to direct that calcium appropriately:

Scenario | Recommendation  
---|---  
— | —  
— | —  
**Vitamin D + calcium supplementation** | K2 non-negotiable  
**Postmenopausal women** | D3 + K2 (MK-7) + adequate protein  
**Men with cardiovascular risk** | D3 + K2 (MK-7); avoid excess calcium  
  
* * *

## The Magnesium Cofactor

Magnesium is required for: \- **Vitamin D metabolism** (conversion in liver and kidney) \- **Osteocalcin carboxylation** (the carboxylase enzyme requires Mg²⁺) \- **ATP-dependent reactions** throughout bone formation

**Practical note** : Ensure adequate magnesium when supplementing D3 + K2. Many patients with cardiovascular risk and osteoporosis are magnesium deficient. See [Magnesium Types and Protocols](magnesium-types.html).

* * *

## Doses in studies

### Approaches Reported in the Literature

_Note: The MK-4 dose used in clinical studies is roughly 200x the typical MK-7 dose because of its short half-life._

### Dietary Sources

Food | K2 Content | Form | Notes  
---|---|---|---  
**Natto** (fermented soybeans) | 100-500 µg per 100g | MK-7 | Most concentrated natural source; acquired taste  
**Gouda cheese** | 75 µg per 100g | MK-7, MK-8 | Good everyday source  
**Brie cheese** | 20-30 µg per 100g | MK-7 | —  
**Egg yolk** | 5-15 µg per 100g | MK-4 | Variable; pasture-raised > conventional  
**Chicken liver** | 15-30 µg per 100g | MK-4 | —  
**Butter** | 10-15 µg per 100g | MK-4 | Variable; grass-fed > grain-fed  
**Dark chicken meat** | 8-10 µg per 100g | MK-4 | —  
**Kefir, kefir cheese** | 5-10 µg per 100g | MK-4, MK-7 | Fermented dairy  
  
* * *

## Testing and Monitoring

### Undercarboxylated Osteocalcin (ucOCN)

  * Direct measure of K2 status
  * Measures the proportion of osteocalcin that lacks sufficient carboxylation
  * Higher ucOCN = greater K2 deficiency
  * Available through specialty labs (e.g., Diagnostics by design, Metabolomic Testing)
  * **Ideal range** : ucOCN should be <20% of total osteocalcin



### dp-ucMGP (dephosphorylated uncarboxylated MGP)

  * Measures vascular K2 status
  * Elevated dp-ucMGP = vitamin K deficiency in vascular tissue
  * Used in research settings; available through some labs
  * **Higher levels** associated with cardiovascular events and mortality



### PIVKA-II (Protein Induced by Vitamin K Absence)

  * Also called PIVKA-II; measures undercarboxylated prothrombin
  * Primarily used for vitamin K1/ clotting factor status
  * Less relevant for K2-specific bone/vascular assessment



### Imaging

Modality | What It Shows | Relevance to K2  
---|---|---  
**Coronary artery calcium (CAC) CT** | Agatston score | Track calcification; respond to K2 intervention  
**Carotid intima-media thickness** | Vessel wall thickness | Subclinical atherosclerosis  
**DEXA bone density** | BMD at hip and spine | Track bone response to D3+K2  
  
* * *

## Safety and Toxicity

### Vitamin K2 has an Excellent Safety Profile

  * **No known toxicity** at any dose studied (well above supplemental levels)
  * Not excreted renally — no kidney toxicity concern
  * No upper tolerable intake level established by any regulatory body
  * **Drug interactions limited** : Warfarin (coumadin) — K2 reverses warfarin effect by activating clotting factors; patients on warfarin need consistent K2 intake and INR monitoring



### Contraindications

Situation | Concern  
---|---  
**Warfarin/Coumadin** | K2 antagonizes anticoagulant effect — discuss with cardiologist  
**Hypercoagulable states** | K2 activates clotting factors — theoretical concern  
**Bile acid malabsorption** | Reduced fat absorption → reduced K2 absorption  
  
* * *

## Notes

  * **RCT evidence gaps** : Large-scale Western RCTs definitively proving K2 reduces cardiovascular events or fractures are still lacking; existing data is encouraging but not conclusive
  * **Dose-response relationship** : Not well established — optimal dose may vary by individual based on gut absorption, microbiome, dietary K1 intake, and metabolic demand
  * **The natto factor** : Japanese populations consuming large amounts of natto have the highest K2 intakes and lower rates of osteoporosis and cardiovascular disease — observational, not causal proof
  * **MK-7 vs. all-trans** : Most commercial MK-7 is "all-trans" (natural form); synthetic "cis" forms exist but are biologically inactive — use reputable brands
  * **The calcium + D3 without K2 problem** : Large WHI trial showed calcium + D3 supplementation modestly increased hip fracture but not overall benefit; K2 co-supplementation may have changed outcomes
  * **Children** : K2 supplementation in growing children is theoretically beneficial for bone development but not well studied



* * *

## Practical Context

### Uses

  1. **Test baseline** (optional): ucOCN, vitamin D level, CAC score if >45
  2. **Retest** : Vitamin D at 3 months, CAC at 2-3 years
  3. **Adjust** : Based on results



### Choosing a K2 Supplement

Quality Marker | What to Look For  
---|---  
**Form** | MK-7 as all-trans menaquinone-7  
**Source** | Natto-derived > synthetic  
**Dose accuracy** | Third-party tested (NSF, USP, ConsumerLab)  
**Fillers** | Avoided for purity; no unnecessary additives  
**Softgel vs. capsule** | Softgels with fat (MCT oil) may improve absorption  
  
### Food-First Approach

  * Add natto to diet if tolerable (fermented soybean; strong flavor)
  * Prioritize grass-fed dairy and butter
  * Pasture-raised egg yolks
  * Fermented cheeses (Gouda, Brie, Edam)
  * Hard cheeses have higher K2 than soft



### When to Consider K2-Specific Testing

  * Known family history of cardiovascular disease
  * Documented coronary artery calcification
  * Osteoporosis diagnosis
  * Long-term statin use (conflicting data on whether statins affect K2-dependent proteins)
  * Malabsorption conditions (bariatric surgery, Crohn's, celiac)



* * *

## Sources

1. NCT04539418 (NCT04539418)